Mark your calenders for Nov 6, 2015

[ashiwi]

en.sanofi.com/investors/events/corporate/2015/2015-11-06_IR_Seminar_Meet_Management.aspx

Meet Sanofi Management

November 06, 2015

Sanofi will organize a Meet Management Seminar
at its Headquarters in Paris on November 6, 2015.

A live webcast of the plenary session will be available
from 8:30 to 10:00 am CET.

Senior management representatives will provide a business update and outline a roadmap towards 2020. We will also present the latest progress of our R&D pipeline.

Related press release

Sanofi Announces New, Global Business Unit Structure to Drive Future Growth


Deepens specialization and allows clear focus on growth drivers
Three, new Global Business Units for General Medicines & Emerging Markets, Specialty Care, and Diabetes & Cardiovascular
Guenter, Meeker and Witz appointed to lead new Global Business Units
Charmeil and Hellmann continue to lead Sanofi Pasteur and Merial
New structure focuses and simplifies the organization to drive growth

Paris, France - July 15, 2015 - Sanofi today announced plans to evolve its business with the creation of five, Global Business Units: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur and Merial. This new structure will be implemented beginning in January 2016. The process of legal and social consultation will be followed as required.

Sanofi's heritage has been formed from a combination of companies that have greater than a century of experience in the pharmaceutical industry. This heritage has enabled Sanofi to deliver highly innovative treatments to address the changing needs of patients, healthcare providers and customers. Sanofi is now poised to achieve significant growth with the potential of launching up to six new medicines in 2015 and approximately one new medicine every six months between 2016 and 2018.

"The new organization simplifies and focuses Sanofi to optimize growth," said Olivier Brandicourt, Chief Executive Officer, Sanofi. "This is a necessary step for ensuring that Sanofi's new medicines and vaccines continue to build on our heritage of providing innovative healthcare therapies."

The General Medicines & Emerging Markets Global Business Unit will be led by Peter Guenter and will consist of Sanofi's Established Products, Generics, Consumer Healthcare, and all pharmaceutical businesses in Emerging Markets.

The Specialty Care Global Business Unit, to be called Sanofi Genzyme, will be led by David Meeker and will consist of Sanofi's medicines in Rare Diseases, Multiple Sclerosis, Oncology and immunology, including the two, investigational biologics, sarilumab and dupilumab.

The Diabetes & Cardiovascular Global Business Unit will be led by Pascale Witz and will consist of Sanofi's Diabetes Care medicines as well as Cardiovascular, which includes Praluent (alirocumab), which is currently under review by the U.S. FDA and the European Medicines Agency (EMA).

Sanofi Pasteur and Merial are both Global Business Units and will continue to manage their current portfolios of vaccines and animal health products. Olivier Charmeil will continue to lead Sanofi Pasteur and Carsten Hellmann will continue to lead Merial.

Similar to Research and Development and Industrial Affairs, all functions will be globalized to better serve the Business Units.

The composition of the Executive Committee remains unchanged. The leadership roles announced today are effective January 1st, 2016.

[lorcan458]

Oct 9, 2015 11:37:01 GMT -5 ashiwi said:

The Diabetes & Cardiovascular Global Business Unit will be led by Pascale Witz and will consist of Sanofi's Diabetes Care medicines as well as Cardiovascular, which includes Praluent (alirocumab), which is currently under review by the U.S. FDA and the European Medicines Agency (EMA).

If my memory is correct, Mannkind's cardiovascular effort is ahead of the pain medication in the Technosphere timeline. I wonder if that's getting a bigger push because of Sanofi putting Diabetes and Cardiovascular in the same unit. Maybe Mannkind is somewhat silent on the slow rollout because they already know Sanofi is their partner for cardio. 

[slugworth008]

Hopefully the word "Afrezza" will be spoken and perhaps even discussed relating to SNY's portfolio. SNY's lack of even mentioning Afrezza has been
somewhat disheartening. IMO

I remain long and optimistic.

[falconquest]

My thoughts exactly Slug. And if Afrezza is not mentioned or mentioned very briefly or only referenced as another therapeutic option, then what? I don't mean to be pessimistic but we all know how Mannkind/Sanofi has been at meeting investor expectations.

[slugworth008]

falconquest: No doubt about that. IMO - SNY needs to place attention on an Afrezza talk track. I understand their stated goal of launching 25 drugs in 5 years - Great. But let's give Afrezza a little love
at the Seminar.

[gamblerjag]

It would be great if SNY would mention something more than We have teamed up with MNKD!!!     I have come to the conclusion (and not upset or frustrated)  that the only thing that will move this stock in the near future is script numbers.  Personally,  I"m throwing Techno applications out for now since we are talking about 3-5 years.  Stocks look 6 months to 1 year out.   Not saying that won't be huge in the future, just not now reflecting in share price.  So unless there is that ever elusive B/O that the other board continually talks about, which I believe almost no one here intelligently believes (especially after hearing Matt's several CC's)  I think we will not see double digits in s/p until perhaps late 2016.  I hope I'm wrong.  Of course if there ever is that elusive B/O..  we will scream pass low double digits. Have a good weekend all.

[mnholdem]

Pascale Witz is the head of the new Diabetes and Cardiovascular Global Business Unit. It's unknown how much time Pascale will be given to speak, but these are the Medicines and Medical Devices found in this newly combined GBU.

DIABETES

en.sanofi.com/products/diabetes/diabetes.aspx

Medicines

Our principal medicinal products in the field of diabetes are:
Lantus® (insulin glargine), a long-acting human insulin analog, market leader for branded insulins (IMS source). Lantus® is available is more than 120 countries worldwide.
Toujeo® (Insulin glargine).
Apidra® (insulin glulisine) a rapid-acting human insulin analog.
Insuman®, a range of rapid- and intermediate-acting human insulins.
Lyxumia® (lixisenatide) is a once-daily prandial GLP-1 receptor agonist.
Amaryl®/Amarel® (glimepiride), a sulfonylurea-class hypoglycemic.
Afrezza® (insulin human) is a rapid-acting, inhaled insulin. Only available in the United-States.

Furthermore, other diabetes treatments are currently in clinical development.
 
Medical devices

®Lantus®, Apidra® and Insuman® are also available in the form of Lantus® SoloSTAR®, Apidra® SoloSTAR® and Insuman SoloSTAR® injection pens.
ClikSTAR®, a reusable pen for Lantus® and Apidra®, is available in more than 30 countries for patients with type 1 or type 2 diabetes.
AllSTAR® is developed especially for people with diabetes in emerging markets, indicated for use with Sanofi’s insulin portfolio. AllStar® is now available in India.
JuniorSTAR®, a reusable insulin pen.

Sanofi has established agreements with several innovative companies to make new therapeutic solutions available to patients. For example, our innovative partnership with AgaMatrix has allowed us to bring to market the BGStar® and iBGStar® blood glucose monitors for patients taking insulin. MyStar Extra®, a blood glucose monitors that provides the patient with an Ab1C estimation, is available since October 2013 in Italy, Spain and France.

-----

CARDIOVASCULAR

en.sanofi.com/products/other_products/other_products.aspx

Sanofi's medicines in the field of cardiovascular disease:

Multaq® (dronedarone) is an antiarrhythmic indicated for the maintenance of sinus rhythm after successful cardioversion in clinically stable adult patients with paroxysmal or persistent atrial fibrillation (AF). Prescribing this drug requires a thorough cardiac examination to ensure the absence of systolic left ventricular dysfunction, or a history of heart failure. Because of its safety profile, it should only be prescribed after alternative treatment has been considered. This antiarrhythmic has demonstrated a significant reduction in cardiovascular hospitalization.

Aprovel® (irbesartan) and CoAprovel® are two major treatments for essential hypertension marketed through an alliance with Bristol-Myers Squibb.

-----

Based on both the number of drugs and the size of sales, I would think the diabetes drugs will take up the lion's share of GBU Witz's presentation. I think Lantus® and Apidra® will barely be mentioned. So how much time do you think will be devoted to Afrezza®? Do you think there may be a possibility of her talking about a Toujeo® + Afrezza® diabetes treatment combination?  

[jpg]

PCSK9 target will be the star attraction of cardio and diabetes followed by Toujeo.

[mnholdem]

Regeneron and Sanofi Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients

www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-fda-approval-of-praluent-alirocumab-injection-the-first-pcsk9-inhibitor-in-the-us-for-the-treatment-of-high-ldl-cholesterol-in-adult-patients-300118572.html

 I assumed that this inhibitor would be discussed during their new drugs / pipeline segment, since I hadn't heard a launch date announced yet. Judging from the Praluent website, they're pretty close (see link below).

www.praluent.com/?utm_source=google&utm_medium=cpc&utm_campaign=dtc_b_dtc%20branded%20praluent%20broad&utm_content=praluent%20brand%20broad&utm_term=praluent&moc=pluco23388ps&gclid=CMmb3cKdxcgCFWRBMgodCIAOOg&gclsrc=ds

So you're probably right about top billing going to Praluent®...